Business EconomyPosted at: Jun 13 2026 7:01PM


Dr Reddy's launches Generic Bosutinib Tablets in US market

Hyderabad, June 13 (UNI) Dr Reddy's Laboratories Ltd on Saturday announced the launch of Bosutinib Tablets 400 mg, a generic equivalent of Bosulif, in the United States, marking its entry as the first generic player in the market for the strength and further expanding its oncology portfolio.
The Hyderabad-based pharmaceutical major said it has partnered with MSN Laboratories Pvt Ltd. for the product. Under the collaboration, Dr Reddy's holds exclusive marketing rights in the United States, while MSN is responsible for product development and manufacturing.
Bosutinib Tablets 400 mg was a first-to-file product and is eligible for 180 days of generic drug exclusivity in the US market, the company said in a statement.
Commenting on the launch, Milan Kalawadia, Chief Executive Officer, North America, Dr Reddy's Laboratories Inc., said the introduction of the product reflects the company's strategy of ensuring timely market entry for high-priority therapies while improving access to affordable treatment options.
"This launch underscores our commitment to expanding access to critical medicines and strengthening our oncology portfolio while supporting patients and healthcare providers with affordable treatment alternatives," he said.
MSN Laboratories Executive Director Bharat Reddy said the successful development and commercialisation of Bosutinib Tablets highlights the company's scientific, regulatory and manufacturing capabilities in complex oncology products.
"We remain committed to delivering high-quality and affordable medicines globally through efficient product development and manufacturing excellence," he said.
According to IQVIA National Sales Perspectives data, the Bosulif brand of Bosutinib Tablets 400 mg recorded sales of approximately USD 253.8 million in the United States during the 12-month period ended April 2026.
UNI KNR SAS
Please log in to get detailed story.
Tags: #Dr Reddy's launches Generic Bosutinib Tablets in US market
More News

India Inc’s spending on CSR hits Rs 40,794 cr in FY2024-25: Report

18 Jul 2026 | 4:05 PM

New Delhi, Jul 18 (UNI) India Inc's spending on Corporate Social Responsibility (CSR) touched a record high of Rs 40,794 crore in FY2024-25, registering a 17pc year-on-year increase, as companies continued to expand investments in education, healthcare and sustainability, according to the Bharat CSR Performance Report 2026 released by consulting and research firm Fulcrum.

see more..

Hesitation biggest obstacle to business success, Sitharaman urges young entrepreneurs to take risks

18 Jul 2026 | 3:46 PM

New Delhi, Jul 18 (UNI) Finance Minister Nirmala Sitharaman on Saturday called upon India's young entrepreneurs to overcome their fear of taking risks, saying the biggest obstacle to business success today is not geography or lack of opportunity, but hesitation.

see more..

Aditya Birla Capital invests Rs 484 50 crore in insurance arm

17 Jul 2026 | 9:39 PM

Mumbai, Jul 17 (UNI) Aditya Birla Capital Ltd (ABCL) officially informed the stock exchanges here on Friday that it has invested Rs 484.5 crore in Aditya Birla Sun Life Insurance Company Ltd (ABSLI) through a rights issue of equity shares. .

see more..

SCCL to prioritise coal supply for Telangana power plants amid rising demand

17 Jul 2026 | 9:27 PM

Hyderabad, July 17 (UNI)The Singareni Collieries Company Limited (SCCL) on Friday said it would accord top priority to coal supplies for Telangana's thermal power stations to ensure uninterrupted power generation amid rising electricity demand under prevailing El Niño conditions.

see more..

BikeWo, Yubhas Renewables partner to pilot solar-assisted electric three-wheelers

17 Jul 2026 | 9:17 PM

Hyderabad, July 17 (UNI) BikeWo Green Tech Limited on Friday said it has partnered with Yubhas Renewables Private Limited to conduct operational validation of solar-assisted electric three-wheelers aimed at improving mobility in rural and semi-urban areas.

see more..